Publisher
Springer Science and Business Media LLC
Reference76 articles.
1. Delveinsight. Treatment-Resistant Hypertension - Market Insight, Epidemiology And Market Forecast - 2032. 2022. https://www.delveinsight.com/report-store/treatment-resistant-hypertension-market.
2. Ojha U, Ruddaraju S, Sabapathy N, Ravindran V, Worapongsatitaya P, Haq J, et al. Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension. Am J Cardiovasc Drugs. 2022;22:271–85.
3. Singh NK, Goyal RK. New Classes of Antihypertensive Drugs: Therapeutic Potentials. Clin Exp Hypertens. 1999;21:137–43.
4. Chen V, Ning H, Allen N, Kershaw K, Khan S, Lloyd-Jones DM, et al. Lifetime Risks for Hypertension by Contemporary Guidelines in African American and White Men and Women. JAMA Cardiol. 2019;4:455.
5. Zhou B, Carrillo-Larco RM, Danaei G, Riley LM, Paciorek CJ, Stevens GA, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–80.